Bioxodes SA, a clinical-stage biopharmaceutical company based in Gosselies, Belgium, announced today that it has received a notice from the European Patent Office (EPO) indicating its intention to grant a patent for BIOX-101 (Ir-CPI), the company's lead asset. This patent further solidifies BIOX-101's protection in thromboinflammation and adds to the company's robust intellectual property portfolio.
Advancing breakthrough treatment
BIOX-101, derived from a protein found in tick saliva, represents a significant advancement in the treatment of thrombotic and inflammatory diseases. The drug has shown promise in preventing blood clot formation without increasing bleeding risks and inhibiting the activation of neutrophils, thus preventing acute neuroinflammatory events associated with intracerebral hemorrhage.
Significant milestone
Marc Dechamps, Chief Executive Officer of Bioxodes, emphasized the importance of the EPO's decision: "The European Patent Office's intention to grant a patent for BIOX-101 in Europe represents a significant milestone for the advancement of this first-in-class drug. It offers breakthrough hope for hemorrhagic stroke patients and demonstrates potential applicability across related conditions."
Clinical development
BIOX-101 is currently in Phase 2a clinical testing in Belgium, with a randomized open-label proof-of-concept study involving 32 patients within the first 72 hours of a hemorrhagic stroke. The drug's unique mechanism of action positions it as a promising candidate for thromboinflammatory diseases, paving the way for innovative treatments in this field.
Strong intellectual property portfolio
Bioxodes has secured significant funding from Belgian investment funds and business angels, including €12 million in non-dilutive funding from the Wallonia region. With both granted and pending patents associated with Ir-CPI worldwide, the company is poised to continue its pioneering work in the prevention and treatment of (thrombo)inflammatory diseases.
The intention of the European Patent Office to grant a patent for BIOX-101 underscores the importance of innovative research in addressing critical medical needs and represents a significant step forward in Bioxodes' mission to transform the landscape of thromboinflammatory disease treatment.